Compare EDUC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | IMNN |
|---|---|---|
| Founded | 1965 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 12.9M |
| IPO Year | N/A | 1985 |
| Metric | EDUC | IMNN |
|---|---|---|
| Price | $1.30 | $3.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | 18.6K | ★ 64.6K |
| Earning Date | 01-09-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,415,900.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $2.99 |
| 52 Week High | $1.93 | $41.22 |
| Indicator | EDUC | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 49.02 |
| Support Level | $1.26 | $2.99 |
| Resistance Level | $1.35 | $4.00 |
| Average True Range (ATR) | 0.07 | 0.30 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 39.39 | 62.79 |
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).